Allogene Therapeutics, Inc. — Director's Dealing 2018

Oct 11, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Allogene Therapeutics, Inc. (ALLO)
CIK: 0001737287
Period of Report: 2018-10-10

Reporting Person: WITTE OWEN N. (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	183750	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Convertible Preferred Stock	$0.00		Common Stock (37432)		Direct

Footnotes

F1: Each share of Series A Convertible Preferred Stock is convertible into 5.25 shares of Common Stock. The Series A Convertible Preferred Stock has no expiration date.